InvestorsHub on MSN
Precision BioSciences reports encouraging muscle improvements in preclinical DMD gene therapy study
Precision BioSciences Inc. (NASDAQ:DTIL) presented new preclinical findings for its PBGENE-DMD gene therapy at the Muscular ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results